Skip to main content
Hikal Ltd. logo

Hikal Ltd. — Investor Relations & Filings

Ticker · HIKAL ISIN · INE475B01022 LEI · 335800OLTGHHYZWTF859 BSE.NS Manufacturing
Open in API
Filings indexed 737 across all filing types
Latest filing 2020-06-18 Regulatory Filings
Country IN India
Listing BSE.NS HIKAL

About Hikal Ltd.

https://www.hikal.com

Hikal Ltd. provides solutions across the life sciences value chain, specializing in the development and manufacturing of active ingredients, intermediates, and formulations. The company operates through two primary business segments: Pharmaceuticals and Crop Protection. In the pharmaceutical division, it focuses on the production of Active Pharmaceutical Ingredients (APIs) and advanced intermediates for various therapeutic areas. The crop protection segment involves the contract manufacturing of pesticides, herbicides, and fungicides for global agrochemical leaders. Hikal offers comprehensive Contract Research and Manufacturing Services (CRAMS), leveraging its research and development capabilities to support clients from early-stage development to commercial-scale production. Its facilities adhere to international quality standards, maintaining a strong track record of regulatory compliance with global health authorities.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2020-06-18 English
Updates
Call Transcript Classification · 95% confidence The document is an invitation to an earnings call scheduled for June 19, 2020, to discuss the financial performance for the quarter and year ended March 31, 2020. It contains no actual financial data or results, only details about the call logistics and participants. The document length is short (2144 characters) and it serves as a notice or invitation rather than a report or transcript. Therefore, it is classified as a Call Transcript (CT) type document, specifically an earnings call invite, which falls under the Call Transcript category.
2020-06-16 English
Updates
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which is a regulatory requirement for listed companies in India to disclose material events or information. The content focuses on the impact of the COVID-19 pandemic on the company's operations, including business operations, employees, raw materials, demand, financial resources, and capex. It is an update on operational and financial impact rather than a full financial report or earnings release. There is no detailed financial data, no quarterly or annual financial statements, no audit opinions, or management discussion and analysis. The document is a regulatory announcement providing material information to the stock exchanges and investors about the company's current status and outlook related to COVID-19. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-06-11 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter from Hikal Ltd. addressed to stock exchanges regarding the trading window closure and reopening dates around the announcement of audited financial results for the quarter and year ended March 31, 2020. It references the upcoming Board meeting to approve these results but does not contain any financial data or the results themselves. The document is short (1656 characters) and serves as an announcement related to trading restrictions rather than a financial report or detailed filing. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2020-06-10 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a formal notice from the company to stock exchanges about an upcoming Board Meeting scheduled for June 18, 2020. The purpose of the meeting is to consider and approve the audited financial results for the quarter and year ended March 31, 2020, and to consider payment of a final dividend. The document does not contain any financial data or results itself, but is an announcement of a future board meeting where such matters will be discussed. The document length is short (1567 characters) and it serves as an intimation or notice rather than a report or detailed filing. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement and notice to exchanges, rather than a full financial report or other specific filing type.
2020-06-10 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 100% confidence The document is a formal disclosure under the Securities and Exchange Board of India (SEBI) regulations, specifically the Substantial Acquisition of Shares and Takeover Regulations, 2011. It reports the promoter's shareholding percentage in Hikal Limited as of March 31, 2020, including details of shares held and confirmation that shares are not encumbered. The document is a notification of shareholding levels by a promoter, which aligns with the definition of a Major Shareholding Notification (MRQ). There is no indication of financial statements, audit information, or other report types. The document is not an announcement of a report publication but a regulatory filing of shareholding information. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2020-05-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.